Myopia News and Research

RSS

Myopia, also called nearsightedness or shortsightedness, is a refractive defect of the eye in which collimated light produces image focus in front of the retina when accommodation is relaxed.

STAAR Surgical's Visian Implantable Collamer Lens featured prominently at 2010 ESCRS Congress

STAAR Surgical Company, the leading worldwide developer, manufacturer and marketer of phakic intraocular lenses, today announced that the Visian Implantable Collamer® Lens (ICL) was featured prominently in more than 40 presentations by leading ophthalmologists at meetings prior to and during the 2010 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) held in Paris, France from September 4 through 8, 2010.

8 Sep 2010

Research links body weight to glaucoma risk

This month's Ophthalmology journal includes surprising research from the Massachusetts Eye and Ear Infirmary on the relation of body weight to the risk for glaucoma. Also, from researchers at the Tokyo Medical and Dental University, comes the first specific map of how the development of myopic maculopathy, an illness that afflicts many severely nearsighted people, predicts which patients will be most susceptible to vision loss.

3 Aug 2010

New myopia control technology for eye health benefits from Vision CRC

Scientists from the Vision Cooperative Research Centre in Australia have announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners – the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

15 Jul 2010

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals is pleased to announce the launch of Neptazane (Methazolamide) 25 mg and 50 mg tablets. Both strengths are available in 90 count bottles.

3 Jul 2010

QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD

QLT Inc. today announced final 24-month results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with exudative (wet) age-related macular degeneration. The purpose of the study was to determine if Visudyne® combined with Lucentis® reduced retreatment rates compared with Lucentis monotherapy, while maintaining similar vision outcomes and an acceptable safety profile.

22 Jun 2010

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

QLT Inc. today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types).

16 Jun 2010

Phakic IOLs safer than laser surgery for correcting moderate short-sightedness

A new type of procedure for correcting short-sightedness could be safer than laser eye surgery, according to a new Cochrane Systematic Review. The study also shows that patients prefer the new procedure, despite there being little difference between the two in terms of improving vision.

12 May 2010

Promising new generation of contact lenses for myopia control

An international team of researchers tested a contact lens that may reduce the progress of nearsightedness, or myopia, by fully correcting the central vision but reducing the relative peripheral farsightedness, or hyperopia.

6 May 2010

$Innovative new contact lens to correct hyperopia without refractive surgery$

Innovative new contact lens to correct hyperopia without refractive surgery

Jaume Pauné, a graduate of the Master's Degree in Optometry and Vision Sciences at the UPC-Barcelona Tech's College of Optics and Optometry, has designed an innovative new contact lens that will improve the vision quality of thousands of people without surgery. The Spanish Association of Opticians and Optometrists has granted its National Award to Mr. Pauné for his innovative work in this field.

20 Apr 2010

STAAR Surgical reports 12% increase in first-quarter 2010 revenue

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that revenue for the first quarter ended April 3, 2010 grew approximately 12% as compared to the first quarter of 2009.

13 Apr 2010

Intermittent exotropia will lead to nearsightedness in most children

Intermittent exotropia, a condition in which the eyes turn outward while looking at an object, occurs in about 1% of American children and is less common than esotropia, where the eyes turn inward. In an article published in the March 2010 issue of the American Journal of Ophthalmology, researchers from the Mayo Clinic and Mayo Foundation, Rochester, MN, followed 135 patients with intermittent exotropia over a 20-year period and found that slightly more than 90% of these children became nearsighted by the time they reached their 20s.

8 Apr 2010

STAAR Surgical Company enters into 'Stipulation for Settlement' to resolve pending disputes

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that STAAR and all other parties to the matters Parallax Medical Systems v. STAAR Surgical Company and Scott C. Moody, Inc. v. STAAR Surgical Company entered into a Stipulation for Settlement that globally resolves all pending disputes among them.

31 Mar 2010

Vision CRC scientists discover new technology to control myopia

Scientists from the Vision Cooperative Research Centre in Australia today announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners - the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

31 Mar 2010

Avedro to acquire Corneal Collagen Crosslinking Phase III study rights from Peschke Meditrade

Avedro, Inc. today announced it has signed a definitive agreement with Swiss-based Peschke Meditrade GmbH to acquire the rights to its Phase III studies of Corneal Collagen Crosslinking for the treatment of progressive keratoconus and post LASIK ectasia. The two randomized, controlled, multi-site clinical trials are designed to assess the safety and efficacy of riboflavin/ultraviolet-A light for halting the progression of these degenerative disorders and the accompanying decline in patient’s visual acuity.

17 Mar 2010

FGX International becomes wholly-owned subsidiary of Essilor

FGX International Holdings Limited announced that it has completed its merger with a subsidiary of Essilor International of Charenton-le-Pont, France.

15 Mar 2010

Essilor International completes acquisition of FGX International Holdings

Essilor International has acquired FGX International Holdings Limited, the North American market leader in the design and sale of non-prescription reading glasses. The transaction was completed following approval by FGX shareholders.

15 Mar 2010

Alcon reports 2009 fourth quarter results

Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.

11 Feb 2010

Millennials overly optimistic about their health despite unhealthy habits

According to Life University, a leading chiropractic college and vital health university, Millennials (ages 15-27), are overly optimistic about their own health, despite admitting to the same unhealthy habits that have caused chronic illness in previous generations.

2 Feb 2010

Highlights of January 2010 'Ophthalmology'

This month's Ophthalmology, the journal of the American Academy of Ophthalmology, includes a research review of the effects of Vitamins C and E and magnesium on diabetic retinopathy and findings from the first large study of vision problems in Hispanic and African-American infants and young children.

5 Jan 2010

QLT Ophthalmics to distribute Visudyne in the U.S. market

QLT Inc. ("QLT" or the "Company") is pleased to announce the establishment of its commercial presence in the United States through a newly formed U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"). QOI will take on the sales and marketing of Visudyne(R) in the U.S.

22 Dec 2009